Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Growth 2024-2030
The report requires updating with new data and is sent in 48 hours after order is placed.
Hereditary Transthyretin Amyloid Neuropathy(ATTRv-PN)is a progressive and debilitating condition caused by the deposition of abnormal transthyretin protein in peripheral nerves.Current therapeutic approaches include stabilizers of transthyretin tetramers such as tafamidis.Other options involve gene silencing therapies like RNA interference(RNAi)with drugs such as patisiran and inotersen,which reduce the production of abnormal transthyretin protein in the liver.
The global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Industry Forecast” looks at past sales and reviews total world Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) sales in 2023, providing a comprehensive analysis by region and market sector of projected Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) sales for 2024 through 2030. With Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) industry.
This Insight Report provides a comprehensive analysis of the global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN).
United States market for Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) players cover Alnylam Pharmaceuticals, Akcea Therapeutics, AstraZeneca, Pfizer, Teva, etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market?
What factors are driving Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market opportunities vary by end market size?
How does Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) break out by Type, by Application?
Hereditary Transthyretin Amyloid Neuropathy(ATTRv-PN)is a progressive and debilitating condition caused by the deposition of abnormal transthyretin protein in peripheral nerves.Current therapeutic approaches include stabilizers of transthyretin tetramers such as tafamidis.Other options involve gene silencing therapies like RNA interference(RNAi)with drugs such as patisiran and inotersen,which reduce the production of abnormal transthyretin protein in the liver.
The global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Industry Forecast” looks at past sales and reviews total world Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) sales in 2023, providing a comprehensive analysis by region and market sector of projected Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) sales for 2024 through 2030. With Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) industry.
This Insight Report provides a comprehensive analysis of the global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN).
United States market for Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) players cover Alnylam Pharmaceuticals, Akcea Therapeutics, AstraZeneca, Pfizer, Teva, etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Transthyretin Tetramer Stabilizer
- RNA Interference
- Antisense Oligonucleotides
- Other
- Hospital and Clinic
- Retail Pharmacies
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Alnylam Pharmaceuticals
- Akcea Therapeutics
- AstraZeneca
- Pfizer
- Teva
- Zydus Pharms
- Avet Pharmaceuticals
- Luoxin Pharmaceutical
- Zhengzhou Taifeng Pharmaceutical
- Shapuaisi Pharma
- Tonghua Zhongsheng Pharmaceutical
What is the 10-year outlook for the global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market?
What factors are driving Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) market opportunities vary by end market size?
How does Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) by Country/Region, 2019, 2023 & 2030
2.2 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Segment by Type
2.2.1 Transthyretin Tetramer Stabilizer
2.2.2 RNA Interference
2.2.3 Antisense Oligonucleotides
2.2.4 Other
2.3 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Type
2.3.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Type (2019-2024)
2.3.2 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue and Market Share by Type (2019-2024)
2.3.3 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sale Price by Type (2019-2024)
2.4 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Segment by Application
2.4.1 Hospital and Clinic
2.4.2 Retail Pharmacies
2.4.3 Other
2.5 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Application
2.5.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sale Market Share by Application (2019-2024)
2.5.2 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue and Market Share by Application (2019-2024)
2.5.3 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sale Price by Application (2019-2024)
3 GLOBAL BY COMPANY
3.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Breakdown Data by Company
3.1.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Annual Sales by Company (2019-2024)
3.1.2 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Company (2019-2024)
3.2 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Annual Revenue by Company (2019-2024)
3.2.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Company (2019-2024)
3.2.2 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Company (2019-2024)
3.3 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sale Price by Company
3.4 Key Manufacturers Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Location Distribution
3.4.2 Players Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR TREATMENT OF HEREDITARY TRANSTHYRETIN AMYLOID NEUROPATHY (ATTRV-PN) BY GEOGRAPHIC REGION
4.1 World Historic Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size by Geographic Region (2019-2024)
4.1.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size by Country/Region (2019-2024)
4.2.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Annual Sales by Country/Region (2019-2024)
4.2.2 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Annual Revenue by Country/Region (2019-2024)
4.3 Americas Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Growth
4.4 APAC Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Growth
4.5 Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Growth
4.6 Middle East & Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Growth
5 AMERICAS
5.1 Americas Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country
5.1.1 Americas Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country (2019-2024)
5.1.2 Americas Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Country (2019-2024)
5.2 Americas Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Type (2019-2024)
5.3 Americas Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Region
6.1.1 APAC Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Region (2019-2024)
6.1.2 APAC Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Region (2019-2024)
6.2 APAC Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Type (2019-2024)
6.3 APAC Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) by Country
7.1.1 Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country (2019-2024)
7.1.2 Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Country (2019-2024)
7.2 Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Type (2019-2024)
7.3 Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) by Country
8.1.1 Middle East & Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country (2019-2024)
8.1.2 Middle East & Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Country (2019-2024)
8.2 Middle East & Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Type (2019-2024)
8.3 Middle East & Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN)
10.3 Manufacturing Process Analysis of Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN)
10.4 Industry Chain Structure of Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN)
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Distributors
11.3 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Customer
12 WORLD FORECAST REVIEW FOR TREATMENT OF HEREDITARY TRANSTHYRETIN AMYLOID NEUROPATHY (ATTRV-PN) BY GEOGRAPHIC REGION
12.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size Forecast by Region
12.1.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Forecast by Region (2025-2030)
12.1.2 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Forecast by Type (2025-2030)
12.7 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Forecast by Application (2025-2030)
13 KEY PLAYERS ANALYSIS
13.1 Alnylam Pharmaceuticals
13.1.1 Alnylam Pharmaceuticals Company Information
13.1.2 Alnylam Pharmaceuticals Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications
13.1.3 Alnylam Pharmaceuticals Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Alnylam Pharmaceuticals Main Business Overview
13.1.5 Alnylam Pharmaceuticals Latest Developments
13.2 Akcea Therapeutics
13.2.1 Akcea Therapeutics Company Information
13.2.2 Akcea Therapeutics Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications
13.2.3 Akcea Therapeutics Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Akcea Therapeutics Main Business Overview
13.2.5 Akcea Therapeutics Latest Developments
13.3 AstraZeneca
13.3.1 AstraZeneca Company Information
13.3.2 AstraZeneca Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications
13.3.3 AstraZeneca Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 AstraZeneca Main Business Overview
13.3.5 AstraZeneca Latest Developments
13.4 Pfizer
13.4.1 Pfizer Company Information
13.4.2 Pfizer Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications
13.4.3 Pfizer Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Pfizer Main Business Overview
13.4.5 Pfizer Latest Developments
13.5 Teva
13.5.1 Teva Company Information
13.5.2 Teva Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications
13.5.3 Teva Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Teva Main Business Overview
13.5.5 Teva Latest Developments
13.6 Zydus Pharms
13.6.1 Zydus Pharms Company Information
13.6.2 Zydus Pharms Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications
13.6.3 Zydus Pharms Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Zydus Pharms Main Business Overview
13.6.5 Zydus Pharms Latest Developments
13.7 Avet Pharmaceuticals
13.7.1 Avet Pharmaceuticals Company Information
13.7.2 Avet Pharmaceuticals Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications
13.7.3 Avet Pharmaceuticals Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Avet Pharmaceuticals Main Business Overview
13.7.5 Avet Pharmaceuticals Latest Developments
13.8 Luoxin Pharmaceutical
13.8.1 Luoxin Pharmaceutical Company Information
13.8.2 Luoxin Pharmaceutical Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications
13.8.3 Luoxin Pharmaceutical Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Luoxin Pharmaceutical Main Business Overview
13.8.5 Luoxin Pharmaceutical Latest Developments
13.9 Zhengzhou Taifeng Pharmaceutical
13.9.1 Zhengzhou Taifeng Pharmaceutical Company Information
13.9.2 Zhengzhou Taifeng Pharmaceutical Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications
13.9.3 Zhengzhou Taifeng Pharmaceutical Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Zhengzhou Taifeng Pharmaceutical Main Business Overview
13.9.5 Zhengzhou Taifeng Pharmaceutical Latest Developments
13.10 Shapuaisi Pharma
13.10.1 Shapuaisi Pharma Company Information
13.10.2 Shapuaisi Pharma Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications
13.10.3 Shapuaisi Pharma Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Shapuaisi Pharma Main Business Overview
13.10.5 Shapuaisi Pharma Latest Developments
13.11 Tonghua Zhongsheng Pharmaceutical
13.11.1 Tonghua Zhongsheng Pharmaceutical Company Information
13.11.2 Tonghua Zhongsheng Pharmaceutical Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications
13.11.3 Tonghua Zhongsheng Pharmaceutical Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Tonghua Zhongsheng Pharmaceutical Main Business Overview
13.11.5 Tonghua Zhongsheng Pharmaceutical Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OFTABLES
Table 1.Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2.Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players ofTransthyretinTetramer Stabilizer
Table 4. Major Players of RNA Interference
Table 5. Major Players of Antisense Oligonucleotides
Table 6. Major Players of Other
Table 7. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales byType (2019-2024) & (K Units)
Table 8. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share byType (2019-2024)
Table 9. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue byType (2019-2024) & ($ million)
Table 10. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share byType (2019-2024)
Table 11. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sale Price byType (2019-2024) & (US$/Unit)
Table 12. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sale by Application (2019-2024) & (K Units)
Table 13. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sale Market Share by Application (2019-2024)
Table 14. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Application (2019-2024) & ($ million)
Table 15. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Application (2019-2024)
Table 16. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sale Price by Application (2019-2024) & (US$/Unit)
Table 17. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Company (2019-2024) & (K Units)
Table 18. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Company (2019-2024)
Table 19. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Company (2019-2024) & ($ millions)
Table 20. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Company (2019-2024)
Table 21. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sale Price by Company (2019-2024) & (US$/Unit)
Table 22. Key ManufacturersTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Producing Area Distribution and Sales Area
Table 23. PlayersTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Products Offered
Table 24.Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Geographic Region (2019-2024) & (K Units)
Table 28. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share Geographic Region (2019-2024)
Table 29. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Geographic Region (2019-2024) & ($ millions)
Table 30. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Geographic Region (2019-2024)
Table 31. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country/Region (2019-2024) & (K Units)
Table 32. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Country/Region (2019-2024)
Table 33. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Country/Region (2019-2024) & ($ millions)
Table 34. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Country/Region (2019-2024)
Table 35. AmericasTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country (2019-2024) & (K Units)
Table 36. AmericasTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Country (2019-2024)
Table 37. AmericasTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Country (2019-2024) & ($ millions)
Table 38. AmericasTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales byType (2019-2024) & (K Units)
Table 39. AmericasTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Application (2019-2024) & (K Units)
Table 40. APACTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Region (2019-2024) & (K Units)
Table 41. APACTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Region (2019-2024)
Table 42. APACTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Region (2019-2024) & ($ millions)
Table 43. APACTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales byType (2019-2024) & (K Units)
Table 44. APACTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Application (2019-2024) & (K Units)
Table 45. EuropeTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country (2019-2024) & (K Units)
Table 46. EuropeTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Country (2019-2024) & ($ millions)
Table 47. EuropeTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales byType (2019-2024) & (K Units)
Table 48. EuropeTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Application (2019-2024) & (K Units)
Table 49. Middle East & AfricaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country (2019-2024) & (K Units)
Table 50. Middle East & AfricaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Country (2019-2024)
Table 51. Middle East & AfricaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales byType (2019-2024) & (K Units)
Table 52. Middle East & AfricaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Application (2019-2024) & (K Units)
Table 53. Key Market Drivers & Growth Opportunities ofTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN)
Table 54. Key Market Challenges & Risks ofTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN)
Table 55. Key IndustryTrends ofTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN)
Table 56.Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58.Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Distributors List
Table 59.Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Customer List
Table 60. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) SalesForecast by Region (2025-2030) & (K Units)
Table 61. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) RevenueForecast by Region (2025-2030) & ($ millions)
Table 62. AmericasTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) SalesForecast by Country (2025-2030) & (K Units)
Table 63. AmericasTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Annual RevenueForecast by Country (2025-2030) & ($ millions)
Table 64. APACTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) SalesForecast by Region (2025-2030) & (K Units)
Table 65. APACTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Annual RevenueForecast by Region (2025-2030) & ($ millions)
Table 66. EuropeTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) SalesForecast by Country (2025-2030) & (K Units)
Table 67. EuropeTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) RevenueForecast by Country (2025-2030) & ($ millions)
Table 68. Middle East & AfricaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) SalesForecast by Country (2025-2030) & (K Units)
Table 69. Middle East & AfricaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) RevenueForecast by Country (2025-2030) & ($ millions)
Table 70. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) SalesForecast byType (2025-2030) & (K Units)
Table 71. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) RevenueForecast byType (2025-2030) & ($ millions)
Table 72. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) SalesForecast by Application (2025-2030) & (K Units)
Table 73. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) RevenueForecast by Application (2025-2030) & ($ millions)
Table 74. Alnylam Pharmaceuticals Basic Information,Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Manufacturing Base, Sales Area and Its Competitors
Table 75. Alnylam PharmaceuticalsTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications
Table 76. Alnylam PharmaceuticalsTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 77. Alnylam Pharmaceuticals Main Business
Table 78. Alnylam Pharmaceuticals Latest Developments
Table 79. AkceaTherapeutics Basic Information,Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Manufacturing Base, Sales Area and Its Competitors
Table 80. AkceaTherapeuticsTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications
Table 81. AkceaTherapeuticsTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 82. AkceaTherapeutics Main Business
Table 83. AkceaTherapeutics Latest Developments
Table 84. AstraZeneca Basic Information,Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Manufacturing Base, Sales Area and Its Competitors
Table 85. AstraZenecaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications
Table 86. AstraZenecaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 87. AstraZeneca Main Business
Table 88. AstraZeneca Latest Developments
Table 89. Pfizer Basic Information,Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Manufacturing Base, Sales Area and Its Competitors
Table 90. PfizerTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications
Table 91. PfizerTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 92. Pfizer Main Business
Table 93. Pfizer Latest Developments
Table 94.Teva Basic Information,Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Manufacturing Base, Sales Area and Its Competitors
Table 95.TevaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications
Table 96.TevaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 97.Teva Main Business
Table 98.Teva Latest Developments
Table 99. Zydus Pharms Basic Information,Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Manufacturing Base, Sales Area and Its Competitors
Table 100. Zydus PharmsTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications
Table 101. Zydus PharmsTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 102. Zydus Pharms Main Business
Table 103. Zydus Pharms Latest Developments
Table 104. Avet Pharmaceuticals Basic Information,Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Manufacturing Base, Sales Area and Its Competitors
Table 105. Avet PharmaceuticalsTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications
Table 106. Avet PharmaceuticalsTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 107. Avet Pharmaceuticals Main Business
Table 108. Avet Pharmaceuticals Latest Developments
Table 109. Luoxin Pharmaceutical Basic Information,Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Manufacturing Base, Sales Area and Its Competitors
Table 110. Luoxin PharmaceuticalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications
Table 111. Luoxin PharmaceuticalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 112. Luoxin Pharmaceutical Main Business
Table 113. Luoxin Pharmaceutical Latest Developments
Table 114. ZhengzhouTaifeng Pharmaceutical Basic Information,Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Manufacturing Base, Sales Area and Its Competitors
Table 115. ZhengzhouTaifeng PharmaceuticalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications
Table 116. ZhengzhouTaifeng PharmaceuticalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 117. ZhengzhouTaifeng Pharmaceutical Main Business
Table 118. ZhengzhouTaifeng Pharmaceutical Latest Developments
Table 119. Shapuaisi Pharma Basic Information,Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Manufacturing Base, Sales Area and Its Competitors
Table 120. Shapuaisi PharmaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications
Table 121. Shapuaisi PharmaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 122. Shapuaisi Pharma Main Business
Table 123. Shapuaisi Pharma Latest Developments
Table 124.Tonghua Zhongsheng Pharmaceutical Basic Information,Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Manufacturing Base, Sales Area and Its Competitors
Table 125.Tonghua Zhongsheng PharmaceuticalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications
Table 126.Tonghua Zhongsheng PharmaceuticalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 127.Tonghua Zhongsheng Pharmaceutical Main Business
Table 128.Tonghua Zhongsheng Pharmaceutical Latest Developments
LIST OFFIGURES
Figure 1. Picture ofTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN)
Figure 2.Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Growth Rate 2019-2030 (K Units)
Figure 7. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth Rate 2019-2030 ($ millions)
Figure 8.Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 9.Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Country/Region (2023)
Figure 10.Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 11. Product Picture ofTransthyretinTetramer Stabilizer
Figure 12. Product Picture of RNA Interference
Figure 13. Product Picture of Antisense Oligonucleotides
Figure 14. Product Picture of Other
Figure 15. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share byType in 2023
Figure 16. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share byType (2019-2024)
Figure 17.Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Consumed in Hospital and Clinic
Figure 18. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Market: Hospital and Clinic (2019-2024) & (K Units)
Figure 19.Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Consumed in Retail Pharmacies
Figure 20. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Market: Retail Pharmacies (2019-2024) & (K Units)
Figure 21.Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Consumed in Other
Figure 22. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Market: Other (2019-2024) & (K Units)
Figure 23. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sale Market Share by Application (2023)
Figure 24. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Application in 2023
Figure 25.Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Company in 2023 (K Units)
Figure 26. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Company in 2023
Figure 27.Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Company in 2023 ($ millions)
Figure 28. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Company in 2023
Figure 29. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Geographic Region (2019-2024)
Figure 30. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Geographic Region in 2023
Figure 31. AmericasTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales 2019-2024 (K Units)
Figure 32. AmericasTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue 2019-2024 ($ millions)
Figure 33. APACTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales 2019-2024 (K Units)
Figure 34. APACTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue 2019-2024 ($ millions)
Figure 35. EuropeTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales 2019-2024 (K Units)
Figure 36. EuropeTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue 2019-2024 ($ millions)
Figure 37. Middle East & AfricaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales 2019-2024 (K Units)
Figure 38. Middle East & AfricaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue 2019-2024 ($ millions)
Figure 39. AmericasTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Country in 2023
Figure 40. AmericasTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Country (2019-2024)
Figure 41. AmericasTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share byType (2019-2024)
Figure 42. AmericasTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Application (2019-2024)
Figure 43. United StatesTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 ($ millions)
Figure 44. CanadaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 ($ millions)
Figure 45. MexicoTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 ($ millions)
Figure 46. BrazilTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 ($ millions)
Figure 47. APACTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Region in 2023
Figure 48. APACTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Region (2019-2024)
Figure 49. APACTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share byType (2019-2024)
Figure 50. APACTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Application (2019-2024)
Figure 51. ChinaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 ($ millions)
Figure 52. JapanTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 ($ millions)
Figure 53. South KoreaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 ($ millions)
Figure 54. Southeast AsiaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 ($ millions)
Figure 55. IndiaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 ($ millions)
Figure 56. AustraliaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 ($ millions)
Figure 57. ChinaTaiwanTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 ($ millions)
Figure 58. EuropeTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Country in 2023
Figure 59. EuropeTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Country (2019-2024)
Figure 60. EuropeTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share byType (2019-2024)
Figure 61. EuropeTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Application (2019-2024)
Figure 62. GermanyTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 ($ millions)
Figure 63.FranceTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 ($ millions)
Figure 64. UKTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 ($ millions)
Figure 65. ItalyTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 ($ millions)
Figure 66. RussiaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 ($ millions)
Figure 67. Middle East & AfricaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Country (2019-2024)
Figure 68. Middle East & AfricaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share byType (2019-2024)
Figure 69. Middle East & AfricaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Application (2019-2024)
Figure 70. EgyptTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 ($ millions)
Figure 71. South AfricaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 ($ millions)
Figure 72. IsraelTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 ($ millions)
Figure 73.TurkeyTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 ($ millions)
Figure 74. GCC CountriesTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 ($ millions)
Figure 75. Manufacturing Cost Structure Analysis ofTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) in 2023
Figure 76. Manufacturing Process Analysis ofTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN)
Figure 77. Industry Chain Structure ofTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN)
Figure 78. Channels of Distribution
Figure 79. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales MarketForecast by Region (2025-2030)
Figure 80. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market ShareForecast by Region (2025-2030)
Figure 81. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market ShareForecast byType (2025-2030)
Figure 82. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market ShareForecast byType (2025-2030)
Figure 83. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market ShareForecast by Application (2025-2030)
Figure 84. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market ShareForecast by Application (2025-2030)
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) by Country/Region, 2019, 2023 & 2030
2.2 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Segment by Type
2.2.1 Transthyretin Tetramer Stabilizer
2.2.2 RNA Interference
2.2.3 Antisense Oligonucleotides
2.2.4 Other
2.3 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Type
2.3.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Type (2019-2024)
2.3.2 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue and Market Share by Type (2019-2024)
2.3.3 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sale Price by Type (2019-2024)
2.4 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Segment by Application
2.4.1 Hospital and Clinic
2.4.2 Retail Pharmacies
2.4.3 Other
2.5 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Application
2.5.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sale Market Share by Application (2019-2024)
2.5.2 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue and Market Share by Application (2019-2024)
2.5.3 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sale Price by Application (2019-2024)
3 GLOBAL BY COMPANY
3.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Breakdown Data by Company
3.1.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Annual Sales by Company (2019-2024)
3.1.2 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Company (2019-2024)
3.2 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Annual Revenue by Company (2019-2024)
3.2.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Company (2019-2024)
3.2.2 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Company (2019-2024)
3.3 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sale Price by Company
3.4 Key Manufacturers Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Location Distribution
3.4.2 Players Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR TREATMENT OF HEREDITARY TRANSTHYRETIN AMYLOID NEUROPATHY (ATTRV-PN) BY GEOGRAPHIC REGION
4.1 World Historic Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size by Geographic Region (2019-2024)
4.1.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size by Country/Region (2019-2024)
4.2.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Annual Sales by Country/Region (2019-2024)
4.2.2 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Annual Revenue by Country/Region (2019-2024)
4.3 Americas Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Growth
4.4 APAC Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Growth
4.5 Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Growth
4.6 Middle East & Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales Growth
5 AMERICAS
5.1 Americas Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country
5.1.1 Americas Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country (2019-2024)
5.1.2 Americas Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Country (2019-2024)
5.2 Americas Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Type (2019-2024)
5.3 Americas Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Region
6.1.1 APAC Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Region (2019-2024)
6.1.2 APAC Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Region (2019-2024)
6.2 APAC Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Type (2019-2024)
6.3 APAC Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) by Country
7.1.1 Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country (2019-2024)
7.1.2 Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Country (2019-2024)
7.2 Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Type (2019-2024)
7.3 Europe Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) by Country
8.1.1 Middle East & Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country (2019-2024)
8.1.2 Middle East & Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Country (2019-2024)
8.2 Middle East & Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Type (2019-2024)
8.3 Middle East & Africa Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN)
10.3 Manufacturing Process Analysis of Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN)
10.4 Industry Chain Structure of Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN)
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Distributors
11.3 Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Customer
12 WORLD FORECAST REVIEW FOR TREATMENT OF HEREDITARY TRANSTHYRETIN AMYLOID NEUROPATHY (ATTRV-PN) BY GEOGRAPHIC REGION
12.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Market Size Forecast by Region
12.1.1 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Forecast by Region (2025-2030)
12.1.2 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Forecast by Type (2025-2030)
12.7 Global Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Forecast by Application (2025-2030)
13 KEY PLAYERS ANALYSIS
13.1 Alnylam Pharmaceuticals
13.1.1 Alnylam Pharmaceuticals Company Information
13.1.2 Alnylam Pharmaceuticals Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications
13.1.3 Alnylam Pharmaceuticals Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Alnylam Pharmaceuticals Main Business Overview
13.1.5 Alnylam Pharmaceuticals Latest Developments
13.2 Akcea Therapeutics
13.2.1 Akcea Therapeutics Company Information
13.2.2 Akcea Therapeutics Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications
13.2.3 Akcea Therapeutics Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 Akcea Therapeutics Main Business Overview
13.2.5 Akcea Therapeutics Latest Developments
13.3 AstraZeneca
13.3.1 AstraZeneca Company Information
13.3.2 AstraZeneca Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications
13.3.3 AstraZeneca Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 AstraZeneca Main Business Overview
13.3.5 AstraZeneca Latest Developments
13.4 Pfizer
13.4.1 Pfizer Company Information
13.4.2 Pfizer Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications
13.4.3 Pfizer Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 Pfizer Main Business Overview
13.4.5 Pfizer Latest Developments
13.5 Teva
13.5.1 Teva Company Information
13.5.2 Teva Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications
13.5.3 Teva Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 Teva Main Business Overview
13.5.5 Teva Latest Developments
13.6 Zydus Pharms
13.6.1 Zydus Pharms Company Information
13.6.2 Zydus Pharms Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications
13.6.3 Zydus Pharms Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Zydus Pharms Main Business Overview
13.6.5 Zydus Pharms Latest Developments
13.7 Avet Pharmaceuticals
13.7.1 Avet Pharmaceuticals Company Information
13.7.2 Avet Pharmaceuticals Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications
13.7.3 Avet Pharmaceuticals Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Avet Pharmaceuticals Main Business Overview
13.7.5 Avet Pharmaceuticals Latest Developments
13.8 Luoxin Pharmaceutical
13.8.1 Luoxin Pharmaceutical Company Information
13.8.2 Luoxin Pharmaceutical Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications
13.8.3 Luoxin Pharmaceutical Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 Luoxin Pharmaceutical Main Business Overview
13.8.5 Luoxin Pharmaceutical Latest Developments
13.9 Zhengzhou Taifeng Pharmaceutical
13.9.1 Zhengzhou Taifeng Pharmaceutical Company Information
13.9.2 Zhengzhou Taifeng Pharmaceutical Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications
13.9.3 Zhengzhou Taifeng Pharmaceutical Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Zhengzhou Taifeng Pharmaceutical Main Business Overview
13.9.5 Zhengzhou Taifeng Pharmaceutical Latest Developments
13.10 Shapuaisi Pharma
13.10.1 Shapuaisi Pharma Company Information
13.10.2 Shapuaisi Pharma Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications
13.10.3 Shapuaisi Pharma Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Shapuaisi Pharma Main Business Overview
13.10.5 Shapuaisi Pharma Latest Developments
13.11 Tonghua Zhongsheng Pharmaceutical
13.11.1 Tonghua Zhongsheng Pharmaceutical Company Information
13.11.2 Tonghua Zhongsheng Pharmaceutical Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications
13.11.3 Tonghua Zhongsheng Pharmaceutical Treatment of Hereditary Transthyretin Amyloid Neuropathy (ATTRv-PN) Sales, Revenue, Price and Gross Margin (2019-2024)
13.11.4 Tonghua Zhongsheng Pharmaceutical Main Business Overview
13.11.5 Tonghua Zhongsheng Pharmaceutical Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OFTABLES
Table 1.Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2.Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players ofTransthyretinTetramer Stabilizer
Table 4. Major Players of RNA Interference
Table 5. Major Players of Antisense Oligonucleotides
Table 6. Major Players of Other
Table 7. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales byType (2019-2024) & (K Units)
Table 8. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share byType (2019-2024)
Table 9. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue byType (2019-2024) & ($ million)
Table 10. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share byType (2019-2024)
Table 11. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sale Price byType (2019-2024) & (US$/Unit)
Table 12. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sale by Application (2019-2024) & (K Units)
Table 13. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sale Market Share by Application (2019-2024)
Table 14. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Application (2019-2024) & ($ million)
Table 15. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Application (2019-2024)
Table 16. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sale Price by Application (2019-2024) & (US$/Unit)
Table 17. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Company (2019-2024) & (K Units)
Table 18. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Company (2019-2024)
Table 19. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Company (2019-2024) & ($ millions)
Table 20. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Company (2019-2024)
Table 21. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sale Price by Company (2019-2024) & (US$/Unit)
Table 22. Key ManufacturersTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Producing Area Distribution and Sales Area
Table 23. PlayersTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Products Offered
Table 24.Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Geographic Region (2019-2024) & (K Units)
Table 28. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share Geographic Region (2019-2024)
Table 29. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Geographic Region (2019-2024) & ($ millions)
Table 30. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Geographic Region (2019-2024)
Table 31. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country/Region (2019-2024) & (K Units)
Table 32. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Country/Region (2019-2024)
Table 33. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Country/Region (2019-2024) & ($ millions)
Table 34. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Country/Region (2019-2024)
Table 35. AmericasTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country (2019-2024) & (K Units)
Table 36. AmericasTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Country (2019-2024)
Table 37. AmericasTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Country (2019-2024) & ($ millions)
Table 38. AmericasTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales byType (2019-2024) & (K Units)
Table 39. AmericasTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Application (2019-2024) & (K Units)
Table 40. APACTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Region (2019-2024) & (K Units)
Table 41. APACTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Region (2019-2024)
Table 42. APACTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Region (2019-2024) & ($ millions)
Table 43. APACTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales byType (2019-2024) & (K Units)
Table 44. APACTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Application (2019-2024) & (K Units)
Table 45. EuropeTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country (2019-2024) & (K Units)
Table 46. EuropeTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Country (2019-2024) & ($ millions)
Table 47. EuropeTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales byType (2019-2024) & (K Units)
Table 48. EuropeTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Application (2019-2024) & (K Units)
Table 49. Middle East & AfricaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Country (2019-2024) & (K Units)
Table 50. Middle East & AfricaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Country (2019-2024)
Table 51. Middle East & AfricaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales byType (2019-2024) & (K Units)
Table 52. Middle East & AfricaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Application (2019-2024) & (K Units)
Table 53. Key Market Drivers & Growth Opportunities ofTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN)
Table 54. Key Market Challenges & Risks ofTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN)
Table 55. Key IndustryTrends ofTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN)
Table 56.Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58.Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Distributors List
Table 59.Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Customer List
Table 60. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) SalesForecast by Region (2025-2030) & (K Units)
Table 61. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) RevenueForecast by Region (2025-2030) & ($ millions)
Table 62. AmericasTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) SalesForecast by Country (2025-2030) & (K Units)
Table 63. AmericasTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Annual RevenueForecast by Country (2025-2030) & ($ millions)
Table 64. APACTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) SalesForecast by Region (2025-2030) & (K Units)
Table 65. APACTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Annual RevenueForecast by Region (2025-2030) & ($ millions)
Table 66. EuropeTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) SalesForecast by Country (2025-2030) & (K Units)
Table 67. EuropeTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) RevenueForecast by Country (2025-2030) & ($ millions)
Table 68. Middle East & AfricaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) SalesForecast by Country (2025-2030) & (K Units)
Table 69. Middle East & AfricaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) RevenueForecast by Country (2025-2030) & ($ millions)
Table 70. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) SalesForecast byType (2025-2030) & (K Units)
Table 71. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) RevenueForecast byType (2025-2030) & ($ millions)
Table 72. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) SalesForecast by Application (2025-2030) & (K Units)
Table 73. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) RevenueForecast by Application (2025-2030) & ($ millions)
Table 74. Alnylam Pharmaceuticals Basic Information,Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Manufacturing Base, Sales Area and Its Competitors
Table 75. Alnylam PharmaceuticalsTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications
Table 76. Alnylam PharmaceuticalsTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 77. Alnylam Pharmaceuticals Main Business
Table 78. Alnylam Pharmaceuticals Latest Developments
Table 79. AkceaTherapeutics Basic Information,Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Manufacturing Base, Sales Area and Its Competitors
Table 80. AkceaTherapeuticsTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications
Table 81. AkceaTherapeuticsTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 82. AkceaTherapeutics Main Business
Table 83. AkceaTherapeutics Latest Developments
Table 84. AstraZeneca Basic Information,Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Manufacturing Base, Sales Area and Its Competitors
Table 85. AstraZenecaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications
Table 86. AstraZenecaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 87. AstraZeneca Main Business
Table 88. AstraZeneca Latest Developments
Table 89. Pfizer Basic Information,Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Manufacturing Base, Sales Area and Its Competitors
Table 90. PfizerTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications
Table 91. PfizerTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 92. Pfizer Main Business
Table 93. Pfizer Latest Developments
Table 94.Teva Basic Information,Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Manufacturing Base, Sales Area and Its Competitors
Table 95.TevaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications
Table 96.TevaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 97.Teva Main Business
Table 98.Teva Latest Developments
Table 99. Zydus Pharms Basic Information,Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Manufacturing Base, Sales Area and Its Competitors
Table 100. Zydus PharmsTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications
Table 101. Zydus PharmsTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 102. Zydus Pharms Main Business
Table 103. Zydus Pharms Latest Developments
Table 104. Avet Pharmaceuticals Basic Information,Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Manufacturing Base, Sales Area and Its Competitors
Table 105. Avet PharmaceuticalsTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications
Table 106. Avet PharmaceuticalsTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 107. Avet Pharmaceuticals Main Business
Table 108. Avet Pharmaceuticals Latest Developments
Table 109. Luoxin Pharmaceutical Basic Information,Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Manufacturing Base, Sales Area and Its Competitors
Table 110. Luoxin PharmaceuticalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications
Table 111. Luoxin PharmaceuticalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 112. Luoxin Pharmaceutical Main Business
Table 113. Luoxin Pharmaceutical Latest Developments
Table 114. ZhengzhouTaifeng Pharmaceutical Basic Information,Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Manufacturing Base, Sales Area and Its Competitors
Table 115. ZhengzhouTaifeng PharmaceuticalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications
Table 116. ZhengzhouTaifeng PharmaceuticalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 117. ZhengzhouTaifeng Pharmaceutical Main Business
Table 118. ZhengzhouTaifeng Pharmaceutical Latest Developments
Table 119. Shapuaisi Pharma Basic Information,Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Manufacturing Base, Sales Area and Its Competitors
Table 120. Shapuaisi PharmaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications
Table 121. Shapuaisi PharmaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 122. Shapuaisi Pharma Main Business
Table 123. Shapuaisi Pharma Latest Developments
Table 124.Tonghua Zhongsheng Pharmaceutical Basic Information,Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Manufacturing Base, Sales Area and Its Competitors
Table 125.Tonghua Zhongsheng PharmaceuticalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Product Portfolios and Specifications
Table 126.Tonghua Zhongsheng PharmaceuticalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 127.Tonghua Zhongsheng Pharmaceutical Main Business
Table 128.Tonghua Zhongsheng Pharmaceutical Latest Developments
LIST OFFIGURES
Figure 1. Picture ofTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN)
Figure 2.Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Growth Rate 2019-2030 (K Units)
Figure 7. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth Rate 2019-2030 ($ millions)
Figure 8.Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 9.Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Country/Region (2023)
Figure 10.Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 11. Product Picture ofTransthyretinTetramer Stabilizer
Figure 12. Product Picture of RNA Interference
Figure 13. Product Picture of Antisense Oligonucleotides
Figure 14. Product Picture of Other
Figure 15. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share byType in 2023
Figure 16. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share byType (2019-2024)
Figure 17.Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Consumed in Hospital and Clinic
Figure 18. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Market: Hospital and Clinic (2019-2024) & (K Units)
Figure 19.Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Consumed in Retail Pharmacies
Figure 20. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Market: Retail Pharmacies (2019-2024) & (K Units)
Figure 21.Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Consumed in Other
Figure 22. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Market: Other (2019-2024) & (K Units)
Figure 23. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sale Market Share by Application (2023)
Figure 24. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Application in 2023
Figure 25.Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales by Company in 2023 (K Units)
Figure 26. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Company in 2023
Figure 27.Treatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue by Company in 2023 ($ millions)
Figure 28. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Company in 2023
Figure 29. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Geographic Region (2019-2024)
Figure 30. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Geographic Region in 2023
Figure 31. AmericasTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales 2019-2024 (K Units)
Figure 32. AmericasTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue 2019-2024 ($ millions)
Figure 33. APACTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales 2019-2024 (K Units)
Figure 34. APACTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue 2019-2024 ($ millions)
Figure 35. EuropeTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales 2019-2024 (K Units)
Figure 36. EuropeTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue 2019-2024 ($ millions)
Figure 37. Middle East & AfricaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales 2019-2024 (K Units)
Figure 38. Middle East & AfricaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue 2019-2024 ($ millions)
Figure 39. AmericasTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Country in 2023
Figure 40. AmericasTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Country (2019-2024)
Figure 41. AmericasTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share byType (2019-2024)
Figure 42. AmericasTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Application (2019-2024)
Figure 43. United StatesTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 ($ millions)
Figure 44. CanadaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 ($ millions)
Figure 45. MexicoTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 ($ millions)
Figure 46. BrazilTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 ($ millions)
Figure 47. APACTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Region in 2023
Figure 48. APACTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Region (2019-2024)
Figure 49. APACTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share byType (2019-2024)
Figure 50. APACTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Application (2019-2024)
Figure 51. ChinaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 ($ millions)
Figure 52. JapanTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 ($ millions)
Figure 53. South KoreaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 ($ millions)
Figure 54. Southeast AsiaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 ($ millions)
Figure 55. IndiaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 ($ millions)
Figure 56. AustraliaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 ($ millions)
Figure 57. ChinaTaiwanTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 ($ millions)
Figure 58. EuropeTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Country in 2023
Figure 59. EuropeTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market Share by Country (2019-2024)
Figure 60. EuropeTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share byType (2019-2024)
Figure 61. EuropeTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Application (2019-2024)
Figure 62. GermanyTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 ($ millions)
Figure 63.FranceTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 ($ millions)
Figure 64. UKTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 ($ millions)
Figure 65. ItalyTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 ($ millions)
Figure 66. RussiaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 ($ millions)
Figure 67. Middle East & AfricaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Country (2019-2024)
Figure 68. Middle East & AfricaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share byType (2019-2024)
Figure 69. Middle East & AfricaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market Share by Application (2019-2024)
Figure 70. EgyptTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 ($ millions)
Figure 71. South AfricaTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 ($ millions)
Figure 72. IsraelTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 ($ millions)
Figure 73.TurkeyTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 ($ millions)
Figure 74. GCC CountriesTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Growth 2019-2024 ($ millions)
Figure 75. Manufacturing Cost Structure Analysis ofTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) in 2023
Figure 76. Manufacturing Process Analysis ofTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN)
Figure 77. Industry Chain Structure ofTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN)
Figure 78. Channels of Distribution
Figure 79. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales MarketForecast by Region (2025-2030)
Figure 80. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market ShareForecast by Region (2025-2030)
Figure 81. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market ShareForecast byType (2025-2030)
Figure 82. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market ShareForecast byType (2025-2030)
Figure 83. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Sales Market ShareForecast by Application (2025-2030)
Figure 84. GlobalTreatment of HereditaryTransthyretin Amyloid Neuropathy (ATTRv-PN) Revenue Market ShareForecast by Application (2025-2030)
